Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) insider Joana Goncalves sold 7,000 shares of the stock in a transaction on Monday, November 16th. The stock was sold at an average price of $100.96, for a total transaction of $706,720.00. Following the sale, the insider directly owned 31,771 shares of the company’s stock, valued at $3,207,600.16. This represents a 18.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Thursday, October 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00.
- On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86.
Oruka Therapeutics Stock Down 5.8%
ORKA opened at $99.24 on Tuesday. Oruka Therapeutics, Inc. has a 12 month low of $25.23 and a 12 month high of $115.51. The firm’s fifty day simple moving average is $89.81 and its 200 day simple moving average is $72.68.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). On average, research analysts predict that Oruka Therapeutics, Inc. will post -2.52 earnings per share for the current year.
Analysts Set New Price Targets
ORKA has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Wedbush reaffirmed an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. BTIG Research reaffirmed a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 10th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Finally, Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $141.80.
View Our Latest Research Report on Oruka Therapeutics
Institutional Investors Weigh In On Oruka Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nykredit A S acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at about $29,000. GAMMA Investing LLC boosted its position in Oruka Therapeutics by 201.6% during the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Orion Capital Management LLC acquired a new position in Oruka Therapeutics during the second quarter valued at approximately $91,000. Sterling Capital Management LLC boosted its position in Oruka Therapeutics by 839.0% during the third quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock valued at $138,000 after purchasing an additional 1,485 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after purchasing an additional 2,033 shares during the last quarter. 56.44% of the stock is owned by institutional investors.
Oruka Therapeutics Company Profile
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Further Reading
- Five stocks we like better than Oruka Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
